22
December
2015
|
00:00
Europe/Amsterdam

FDA Approves BIOTRONIK Iperia ICD Systems with Full-Body ProMRI Technology

BIOTRONIK’s Iperia Series of ICDs and Leads Allow Broadest Range of Patient Access to MRI Diagnostic Options

LAKE OSWEGO, Oregon, December 22, 2015 – BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced today that it has received Food and Drug Administration (FDA) approval for use of its latest family of implantable cardioverter defibrillator (ICD) systems with magnetic resonance imaging (MRI) scans. BIOTRONIK ProMRI® technology allows patients with approved device systems to have 1.5 Tesla MRI scans without an exclusion zone. ICD patients will have expanded access to MRI diagnostic scans, which can be critical for diagnosing conditions such as stroke, brain and cardiac tumors or orthopedic injuries.

The BIOTRONIK ProMRI ICD family approval includes the Iperia DR-T in both DF-1 and DF4 configurations; and the Iperia DX System, the only ICD hybrid that combines the benefits of both single- and dual-chamber devices.

Also included is Inventra ProMRI DX, which is the only ICD available that offers ultra-high energy (42 Joules) on the first shock, for patients with complex heart conditions who may require a higher-powered first shock for effective therapy. The devices are MR conditional when used with appropriate BIOTRONIK leads to complete the approved ProMRI system.

MRI scans are used to diagnose a multitude of conditions, especially those involving “soft” tissue like heart, brain, muscles and liver. Seventy-five percent of patients with an implantable electronic device (pacemaker or ICD) will need an MRI in their lifetime1. Until recently, people with ICDs were denied access to MRIs. BIOTRONIK is one of the first companies in the U.S. with ICDs that allow this access, following the first FDA approval in September 2015.

“We have truly entered a new era of total health care for cardiac rhythm management patients who rely on ICDs to monitor their hearts and provide life-saving therapy when demanded,” said Mark A. Marieb, MD, clinical director of Electrophysiology at Yale-New Haven Hospital and Yale School of Medicine in New Haven, Conn., and an investigator in the ProMRI Clinical Study.

“Devices that are tested to be safe and approved by the FDA for use in MRI scans provide assurance to patients and all of their current and future healthcare providers that this therapy will not create a compromise for other diagnostic needs in the patients’ lifetimes,” Dr. Marieb added.

This industry-leading FDA approval is the third in the last 18 months for BIOTRONIK ProMRI technology. “Our goal is to integrate ProMRI technology across our entire line of implantable systems, and in doing so, provide access to MRI diagnostic scans for all CRM patients,” said Marlou Janssen, President, BIOTRONIK, Inc.

“The ProMRI Study and subsequent FDA approvals have been part of a consistent and methodical process for making more MRI options available for U.S. cardiac device patients, starting with single- and dual-chamber pacemakers with an exclusion zone in May 2014, then full-body for the same pacemaker lines in March 2015, and now ICDs for full-body scans, including BIOTRONIK’s unique DX device system. This is meaningful technology that will enhance the quality of healthcare for patients throughout their lives,” Marlou Janssen added.

  1. Roguin A, et al. Europace. 2008; 10(3).
  2. Varma N, et al. Circ: Arrhythmia Electrophysiology. 2010 Oct;3(5).
  3. Hindricks G. et al. The Lancet. 2014, 384(9943).
  4. Data on file.

About BIOTRONIK:

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.